Prof. Dr. Nejat Düzgüneş Appointed Editor-in-Chief of Therapeutics

We are pleased to announce that Prof. Dr. Nejat Düzgüneş has been appointed Editor-in-Chief of Therapeutics (ISSN: 2813-9909).

Prof. Dr. Nejat Düzgüneş is currently a professor in the Department of Biomedical Sciences at the University of the Pacific Arthur A. Dugoni School of Dentistry, USA.

He received his B.Sc. in physics in 1972 at the Middle East Technical University in Ankara, Turkey, and he was awarded his Ph.D. in biophysical sciences at the State University of New York in Buffalo, New York, USA, in 1978. He was a National Cancer Institute National Research Service Award Post-doctoral Fellow in the laboratory of the late Prof. Demetrios Papahadjopoulos at the Cancer Research Institute at UCSF and, he later served there as an Assistant Research Biochemist and Associate Research Biochemist. He was also appointed as an Adjunct Associate Professor in the Department of Pharmaceutical Chemistry at the same university. He worked on the development and application of pH-sensitive liposomes; liposome-mediated therapy of Mycobacterium avium-intracellulare infections; and the fusion of the influenza virus, HIV-1, and SIV with host cells.

In 1990, he was appointed Chair of the Department of Microbiology at the University of the Pacific, and he was then appointed as a professor there in 1995. He and his team worked on the delivery of various antiviral agents, including protease inhibitors and antisense oligonucleotides, to HIV-1-infected cells, and they also worked on gene therapy in regard to HIV-1. His group has worked on the treatment of Candida infections and broadly neutralizing anti-HIV-1 antibodies, as well as suicide gene therapy and photodynamic therapy of oral cancer.

He is the recipient of the Japan Society for the Promotion of Science Fellowship Award (1988) and the United Methodist University Teacher/Scholar Award (2015). Prof. Dr. Düzgüneş has received grants from the American Heart Association, the National Institutes of Health (including R01, U01 and SBIR grants), and the California University AIDS Research Program.

We are very much looking forward to working with Prof. Dr. Düzgüneş. He can rely on the support of our editorial team, and we wish him every success in his new position. For more information on Prof. Dr. Düzgüneş’s vision for Therapeutics, please see the editorial “Welcome to Therapeutics: A Note from the Editor-in-Chief”.

Therapeutics Editorial Office